FY2025 EPS Estimates for AxoGen Raised by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for AxoGen in a note issued to investors on Monday, March 31st. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of ($0.11) per share for the year, up from their previous estimate of ($0.12). The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen’s FY2026 earnings at $0.04 EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at $0.34 EPS.

A number of other equities research analysts have also recently commented on AXGN. Canaccord Genuity Group increased their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price objective on shares of AxoGen in a research report on Wednesday, March 5th. Finally, Lake Street Capital began coverage on AxoGen in a report on Monday, March 17th. They issued a “buy” rating and a $30.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, AxoGen has a consensus rating of “Buy” and a consensus price target of $22.60.

AxoGen Stock Performance

Shares of AxoGen stock opened at $17.81 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The stock has a market cap of $789.77 million, a price-to-earnings ratio of -55.66 and a beta of 1.02. AxoGen has a 1 year low of $5.55 and a 1 year high of $21.00. The firm’s 50-day moving average is $18.26 and its 200 day moving average is $15.93.

Institutional Investors Weigh In On AxoGen

A number of hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC lifted its position in AxoGen by 86.7% during the fourth quarter. Squarepoint Ops LLC now owns 55,668 shares of the medical equipment provider’s stock valued at $917,000 after purchasing an additional 25,853 shares in the last quarter. State of Wyoming bought a new position in shares of AxoGen in the fourth quarter worth about $31,000. ProShare Advisors LLC bought a new position in shares of AxoGen in the fourth quarter worth about $197,000. Nicholas Investment Partners LP lifted its position in shares of AxoGen by 49.9% during the 4th quarter. Nicholas Investment Partners LP now owns 295,554 shares of the medical equipment provider’s stock valued at $4,871,000 after buying an additional 98,419 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of AxoGen by 4.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock valued at $398,000 after acquiring an additional 926 shares during the period. Institutional investors own 80.29% of the company’s stock.

Insider Buying and Selling at AxoGen

In related news, insider Erick Wayne Devinney sold 15,111 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now directly owns 217,762 shares in the company, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the sale, the director now directly owns 97,899 shares of the company’s stock, valued at approximately $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.